Archive

Archive for the ‘Health Care’ Category

Study finds magnesium sulfate may offer protection from cerebral palsy

February 10th, 2011

[ Back to EurekAlert! ]Public release date: 10-Feb-2011 [ | E-mail | Share Share ] Contact: Vicki Bendurevicki@bendurepr.com202-374-9259Society for Maternal-Fetal Medicine

SAN FRANCISCO (February 10, 2011) ? in a study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, the Pregnancy Meeting ?, in San Francisco, researchers will present findings that showed that in rats, the use of magnesium sulfate (Mg) significantly reduced the neonatal brain injury associated with maternal inflammation or maternal infection.

Magnesium sulfate is sometimes used during preterm labor to reduce the risk of neonatal brain injury. in 2010 the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine issued an opinion that “available evidence suggests that magnesium sulfate given before anticipated preterm birth reduces the risk of cerebral palsy in surviving infants.”

“We knew there were indications from other studies that magnesium sulfate might protect a preterm fetus from cerebral palsy, but we wanted to demonstrate direct and conclusive protective effect on the offspring brain in cases of maternal inflammation” said Ron Beloosesky, M.D., one of the study’s authors. “We wanted to learn more about the protective effects of Mg in cases where maternal inflammation causes preterm birth, so we used the very sensitive diffusion tensor imaging, Magnetic Resonance Imaging to study how Mg works.”

Beloosesky and his colleagues studied pregnant Sprague-Dawley rats at 18 days gestation that received i.p. LPS (500 μg/kg) or saline at time 0. Dams were randomized to treatment with s.c. saline or Mg (270 mg/kg loading followed by 27 mg/kgq20 min) for two hours prior to and following the i.p. LPS or saline. Pups were delivered spontaneously (e21) and allowed to mature until postnatal day 25. Female offspring (4-8 per group) were examined under isoflurane anesthesia by MRI brain imaging and analyzed using voxel based analysis (VBA) after spatial normalization. T2 relaxation time was used to assess for white matter injury and diffusion tensor imaging for Fractional Anisotropy (FA) comparison.

The results showed that offspring of LPS-treated dams exhibited significantly increased T2 levels, and reduced FA levels in white and gray matter (eg, corpus callosum, thalamus, hippocampus), consistent with diffuse cerebral injury. in contrast, offspring of Mg-treated LPS dams demonstrated similar T2 and FA levels as control in both white and gray matter.

The study concluded that Mg treatment significantly reduced evidence of neonatal brain injury associated with maternal LPS. these studies suggest that maternal Mg therapy may be most effective in human preterm deliveries associated with maternal/fetal inflammation.

“The next step, said Beloosesky, “is to do more studies to understand exactly how the Mg works and protects the fetal brain.”

###

For interviews or a copy of the abstract please contact Vicki Bendure at , or 202-374-9259.

The Society for Maternal-Fetal Medicine (est. 1977) is a non-profit membership group for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine. the society is devoted to reducing high-risk pregnancy complications by providing continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. the group hosts an annual scientific meeting in which new ideas and research in the area of maternal-fetal medicine are unveiled and discussed. for more information, visit smfm.org.

[ Back to EurekAlert! ] [ | E-mail | Share Share ]  

family Planning Contraception , ,

Acceptable consequences of screening for prostate cancer

January 27th, 2011

The results were published in the prestigious journal The Lancet Oncology. The study included 10,000 men (the screening group) aged 50-64 years who were randomly assigned to regular blood samples to check their level of a prostate cancer marker known as PSA (Prostate- Specific Antigen) every two years, and 10,000 men who were randomly assigned not to be screened (the control group).

The study showed that regular PSA-screening nearly halved the mortality from prostate cancer after 14 years. The screening was, however, associated with a certain risk of over-diagnosis.

The study is one of five papers in the thesis presented by Sigrid Carlsson, M.D., Ph.D. The thesis also includes an investigation of the side-effects that screening caused. Most of the men who were detected by screening to have early, localised prostate cancer and who were treated with curative intent underwent surgery (radical prostatectomy).

“We analysed the side effects of surgery based on how these can be measured relative to the reduced mortality from the disease”, says Sigrid Carlsson from the Department of Urology at the Sahlgrenska Academy.

The results presented in her thesis show that for each man whose life was saved by PSA screening, four more men will become impotent or sexually inactive, while less than one more man will experience problems with urinary incontinence. These figures are lower than those expected by the scientists.

“There is a significant risk of affecting the sexual performance. Most men who undergo surgical treatment for prostate cancer become impotent. but if this is seen in the light of the benefit of a lower mortality, then the side-effects do not appear to be as large as sometimes claimed, particularly if we view the situation from a wider perspective. On the individual level, however, it is clear that there may be considerable suffering”, says Sigrid Carlsson.

The thesis reveals also a tendency for men in the screening group who underwent surgery for prostate cancer to be affected by impotence at a lower degree than those in the control group who underwent surgery. it was also shown that few men experienced that PSA sampling and taking biopsies from the prostate causedparticularly high levels of anxiety. furthermore, serious life-threatening complications from the biopsy procedure or from prostate surgery were very uncommon.

The thesis makes clear the advantages and disadvantages of PSA screening, but the scientists do not believe that the time is right to recommend general screening. In addition, the screening study is still ongoing in Gothenburg.

“We need more studies and a longer follow-up. we also need studies on cost-effectiveness, in combination with measurements of the men’s quality of life”, says Sigrid Carlsson.

impotence Aids , , , ,

Organised crime in Mexico: Under the volcano

October 29th, 2010

THE drugs business, as Miguel tells it, used to offer a promising career for a young man. At 4am he would set out into the sierra of Sinaloa to pick up cannabis. Back in the city of Culiacán he would pack it for export, compressing it with a hydraulic pump, wrapping it in polythene and dunking it in wax to trick the sniffer dogs. The packets would go in trucks, cars, even on push-bikes. Once, in a friend’s Cessna, he skimmed the treetops south to Colombia, dropping packets of cocaine over the Mexican desert on the way back.

Miguel’s trafficking career ended in 1988, when he was caught. Five years in prison followed. “There was always the danger of being captured by the police or the army,” he says now. “But in Sinaloa we had no problems with the other cartels. It was easier to work with them than to kill them. Today they don’t understand that.”

Indeed they don’t. Since Felipe Calderón began his presidency in 2006 with a renewed effort against the drugs cartels, more than 28,000 people have been killed. Mr Calderón has deployed 50,000 soldiers to fight the gangsters, whose inventories now include rocket-propelled grenades, helicopters and semi-submersible vessels. Pitched battles between the army and the traffickers have caused some of these casualties; more still have been caused by fighting among Mexico’s half-dozen main trafficking organisations, engaged in a bloody struggle for the trade.

Last year Mexican officials angrily rebuffed a Pentagon study arguing that the country was in danger of becoming a failed state. That description still seems absurd in most of the country, the world’s 11th-largest by population and 14th-biggest by size of economy. Most of the violence remains confined to a handful of states, mainly close to the United States border. But since the Pentagon’s report the frequency of gang-related homicides has more than doubled. The second quarter of this year saw more than 4,000 such murders: twice as many as at the beginning of last year, and some eight times more than at the beginning of 2007 (see chart 1). The gangs’ tactics now include detonating car-bombs in public places.

The conflict has become a test of endurance for both the government and the narcos. Mr Calderón has staked his presidency on the outcome. In 2007 a third of Mexicans thought the death toll was an acceptable price to pay for beating the cartels, whereas now only a quarter do. “Unless there is a big change in the level of violence, the current strategy cannot survive more than another six months,” says Jorge Castañeda, a former foreign minister.

With a presidential election less than two years away, groups are positioning themselves to influence the next regime. The criminals are, too: heads tossed onto dance floors, corpses strung from bridges and, most recently, a victim’s face that was flayed off to be sewn onto a football, are all messages to government and citizens to back down. The law-abiding must decide whether it is better to give in, or battle on.

The official murder rate in Mexico remains lower than in much of Latin America. In 2009 it was 14 per 100,000 people, compared with 25 in Brazil and around 70 in parts of Central America. The violence is localised: 80% of the gang-related murders since 2006 have been committed in just 7% of Mexico’s towns, according to the government. A third of Mexico’s 31 states have murder rates hovering around five per 100,000, about the same as the United States. Yucatán, where tourists snorkel with whale sharks, sees fewer killings per person than Canada.

Many believe that the official statistics do not capture the whole picture. Cartels are good at public executions, but they are also skilled at hiding bodies when necessary. El pozolero (“the soup-maker”), dissolved some 300 corpses in a broth of acid before his capture last year. In June some 55 bodies were discovered in a silver mine close to Taxco, a tourist-friendly town in Guerrero. A study commissioned by FLACSO, a Latin American social-science university, estimated that, based on victimisation surveys, Mexico’s murder rate could be closer to 26 per 100,000.

What makes Mexico worrying is not just the raw numbers but the power of the cartels over society. Around five years ago Mexico’s drug-smuggling gangs overtook Colombia’s in resources and manpower, reckons Scott Stewart of Stratfor, a Texas-based security consultancy. As well as expanding down the supply chain, running distribution networks in the United States, they have moved up it, buying cocaine directly in Colombia, Bolivia and Peru. They have become a bigger influence in politics at home: woe betide public figures who do not march to their tune.

In Tamaulipas, a state in the north-east bordering Texas, the candidate widely expected to be elected governor in July was murdered four days before the poll. After the discovery of 72 murdered Central and South American migrants in the same state in August, two policemen running the investigation were killed. Journalists in towns such as Reynosa, on the Texan border, have stopped reporting on the drugs wars after being intimidated. Across Mexico, at least 11 mayors have been murdered so far this year.

Violence reaches the rich

But this year has also seen a significant change. Since a bust-up between the Gulf cartel and their former allies, a group known as the Zetas—former Mexican special forces who defected to the narcos a decade ago—violence has spread to the doorsteps of some of Mexico’s richest people. Monterrey, a city of 4m in the state of Nuevo León, daytripping distance from Texas, is Mexico’s industrial powerhouse, with an average income three times the national average, thanks to factories turning out everything from fridges to fuselages for the United States. Smartly-dressed young executives devouring business manuals land at its airport on the hour, every hour.

Yet fighting between the Zetas and the Gulf has destroyed Monterrey’s reputation as a safe city. Though business has more or less held up so far, a series of drug-related spectaculars sparked an exodus of the city’s upper class this summer. In April several people were kidnapped from the Holiday Inn, in the city centre. In August a shoot-out outside the American School left two dead. Many wealthy Mexicans have moved their families to the United States or safer parts of Mexico. In the smart suburbs, Monterrey’s rich are now keeping their SUVs garaged out of sight.

The threat against Mexico’s industrial capital has raised the stakes. “Monterrey will be a decisive battle,” says Luis Rubio, head of CIDAC, a Mexico City think-tank. The country’s movers and shakers have been galvanised now. In August Lorenzo Zambrano, the chairman and CEO of Cemex, the world’s biggest building-materials supplier, which built its empire out of the limestone cliffs of Monterrey, vented his anger on Twitter. “He who leaves Monterrey is a coward,” he wrote. In the same month Monterrey business leaders took out full-page ads in the national press, criticising the government’s apparent impotence. The pressure has had some effect. Last October Nuevo León had 60 federal police officers; it now has 550. “I feel that the sense of urgency has now reached our government,” says Mr Zambrano.

The war has certainly exposed the weakness of Mexico’s criminal-justice institutions. Numbers are not the problem: with 366 officers per 100,000 people, Mexico is better supplied with police than the United States, Britain, Italy and France, among others. But it is badly organised and corrupt. Policemen earn an average of $350 a month, about the same as a builder’s labourer, meaning that wages are supplemented with bribes. Carlos Jáuregui, who was Nuevo León’s chief security official until March, reckons that more than half the officers in the state were being paid by organised crime. A policeman in Monterrey can be bought for about 5,000 pesos ($400) a fortnight, Mr Jáuregui reckons.

“Police are treated as second-class citizens,” says Ernesto López Portillo, head of Insyde, a Mexico City think-tank. They are kept that way by the constitution, which separates police officers from other public servants, meaning they do not qualify for the standard minimum wage and the 40-hour weekly work limit. Police forces are in theory overseen by internal investigation units, but their findings are secret and, in any case, Mr López Portillo estimates that fewer than 5% of forces have such a body.

The government has focused on reforming the federal police, with some success. The force has gone through a deep purge, with a tenth of its officers sacked in the first eight months of this year for corruption or incompetence. Pay has gone up, and so has recruitment. At the beginning of Mr Calderón’s term there were 6,000 officers in the federal force; now there are more than 30,000 (some seconded from the army). The government is developing an external body to review the police.

Progress has also been made on Mexico’s federal prisons, with the construction of a new academy to train prison guards. The Mérida initiative, under which the United States provides help to Mexico to combat organised crime, is being tweaked to back such reforms. Whereas in 2008 most of the budget went on hardware—both military and civilian—the priority now is stronger institutions, says an American embassy official. Change is coming to the judicial system too, after a constitutional reform in 2008 that will set up a British or American-style accusatorial, oral system in place of written investigations, which are open to abuse.

Trials and hold-ups

Yet many reforms take agonisingly long to appear. An exam introduced two years ago to weed out dim or corrupt policemen has been taken by fewer than a quarter of officers, and by fewer than a tenth of state police. Progress on judicial reform has been glacial, meeting enormous resistance. The change is supposed to be completed by 2016; Alejandro Poiré, the government’s security spokesman, says this timetable may have to be speeded up.

In many cases Mexico’s federal system of government has prevented reforms from filtering through to ground level. Mexico is a federation of 31 states and 2,456 municipalities, whose governors and mayors guard their limited powers jealously. Policing is one of them, and the quality varies wildly: there are fewer than half as many local police per head in Tamaulipas as in Tabasco. Some 400 towns have no police, and 90% of municipal forces employ fewer than 100 officers.

Some mayors are under enormous pressure from criminals to keep things that way. Municipal police “are the most vulnerable…the most subjected to intimidation and, of course, the vengeance of the criminals,” Mr Calderón said recently. They are also among the least effective: the patchwork of command muddles operations. In Monterrey the metropolitan area alone has 11 different forces, using different training, tactics and even brands of radio. “If a criminal crosses the street he has reached a safe haven,” admits one official. On October 6th Mr Calderón presented plans to unify the police in each state, bringing the municipal forces under the control of governors. The measure now has broad support in Mexico City but requires changes to the constitution, which more than half the states must approve.

It is a similar story with the prisons. The American official estimates that whereas federal prisons are about a quarter of the way towards being fit for purpose, the state prisons are only a tenth of the way there. Recent mass-jailbreaks in Tamaulipas and an extraordinary episode in Durango, in which prisoners were let out to commit contract killings using guards’ weapons, underline how far state prisons have to go.

In the case of money laundering, the federal government’s recent legislation will be stymied by the fact that property, a favourite way to hide dirty money, is registered at state level. Only the federal district of Mexico City has its own financial-investigations unit.

Yet the government’s reforms, coupled with pressure from the army, may be starting to have an effect. The most visible successes of recent months have been the capture or killing of a string of cartel leaders. Long lines of deputies wait to inherit their positions. But the arrests are a sign of improved intelligence capability in the security forces, says Mr Poiré. Between June and August the murder rate stabilised, at a rate of about 49 gang-killings a day, and it fell somewhat in September, to 36 a day (figures were available only up to September 24th). There have been false dawns before. But it may be that a combination of institutional reform and firepower is slowly beginning to weaken the cartels, or at least alter their behaviour.

In Monterrey the state government is experimenting with an ad-hoc unified force that gives municipalities the right to opt out. Officials reckon that seven of the 11 municipalities will take part. In another experiment, police are patrolling with soldiers and prosecutors to provide a mixture of firepower and basic policing know-how (such as blocking the backs of houses before going in at the front). Since August the city has seen no roadblocks set up by the gangsters, and the level of violence diminished in September. Many locals fear that the respite is temporary, but Javier Treviño, the deputy governor of Nuevo León, believes Monterrey is now over the worst.

The battlefield provides some evidence that certain cartels are being weakened. The Zetas, for instance, seem less and less professional. Some are teenagers who have little idea how to use their powerful weapons. Arrested gunmen are sometimes so drunk or stoned that they have to be left for 24 hours to sober up, one official says. The cartel appears to be relying more on part-time help: one Monterrey businessman found that his office cleaner was working nights for the mob. Many bodies go unclaimed, suggesting that footsoldiers are being recruited, or pressganged, from farther afield. The migrants murdered in Tamaulipas are believed to have been murdered after refusing to work for the narcos.

The weakening of some criminal gangs has had unforeseen consequences. Cartel recruitment has been ramped up in poor neighbourhoods such as Colonia Independencia, a hillside settlement that confronts Monterrey’s government offices from across the Santa Catarina river. Teenagers there run murderous errands for around 4,000 pesos a week, community workers say. And the loss of influence by the Zetas has led to scrappy turf wars. Over the summer Monterrey’s middle class was shocked by the apparently random kidnapping of young, affluent residents. It later emerged that the Zetas were nabbing people who looked like cocaine users to find out where they got their drugs, so that they could kill their rival dealers.

The big green hole

As pressure is put on the drugs business, the gangs are diversifying into other rackets: extortion and kidnap, particularly of migrants from Central America. Gangs increasingly aim to dominate all criminal enterprises in a given territory, rather than simply the supply of drugs, says Antonio Mazzitelli, the head of the UN Office on Drugs and Crime (UNODC) in Mexico City. The increase in kidnapping has heightened the feeling of insecurity, even among those with protection. Diego Fernández, a former presidential candidate who remains influential within the ruling National Action Party, was kidnapped in May and is now seen only in periodic ransom demands, thinner in each photograph.

Even when the cartels are driven out of one place, they tend to pick up their operations elsewhere. Commanders in Monterrey say that their successes have exacerbated problems in the nearby states of Coahuila and Durango. Mexico’s own drugs problems took off in the 1990s, after the old cocaine-trafficking route to Florida through the Caribbean was shut down by the Americans. Now, as Mexico piles pressure on its home-grown cartels, some are moving their operations south. Already, more cocaine is seized in Central America than in Mexico (see chart 2). Some Mexican groups have set up training camps and storage facilities in the jungles of Petén, a “big green hole of nothing” in northern Guatemala, according to Mr Stewart.

The Zetas, in particular, are visible in Central America. Zeta recruitment banners have been spotted, tempting soldiers away from the army with better wages and food; the gang is believed to linked up with former Guatemalan special forces, enthusiastic abusers of human rights during the country’s civil war. In September a Guatemalan court convicted six Mexican nationals, believed to be Zetas, of the murder of 11 people in 2008. In the first six months of this year Guatemalan authorities seized cash, drugs and arms worth more than everything they had seized the previous year, according to the police.

Guatemala’s deepening nightmare could eventually mean grim relief for Mexico. So too could developments in the United States and Europe. On November 2nd California will vote on a ballot initiative to legalise the sale of cannabis which, if it became law, would remove one small line of business from Mexico’s cartels (see article). Legally or not, more cannabis is being grown north of the border anyway.

Help may also come from Europe’s cocaine market. This is now almost as valuable as that of the United States, which is shrinking, according to the UNODC. Andean cocaine bound for Europe need not go through Mexico, and the Mexican gangs are still weaker than the Colombians in Spain (partly because the Mexican diaspora does not extend much beyond the United States). Mr Mazzitelli says Mexicans are now collaborating with the Italian ’Ndrangheta mafia to explore new opportunities in Australia, where the retail price of cocaine is twice what it is in the United States.

Whether its bases are in Mexico or elsewhere, the illegal drugs business will continue to bring violence and corruption to the Americas, where it sucks in an ever greater number of young men. Miguel, the former Sinaloa trafficker, promised his family he would go clean when he got out of jail; he works as a gardener now, but the money is poor, and he would still go into the drugs business if he had his time again. Trying to stop the gangsters “is like mowing the grass,” he says. “You can cut it down. But it always grows back.”

impotence Aids , , , , ,

The US Government, Government of Guyana, and Pharmaceutical Companies Partner …

September 25th, 2010

Here are some suggestions for finding information on the U.S. Department of State website.

  • Check our “A to Z subject index” for topics, countries, or organizations
  • Try the Search, Browse by, or Quick Links options on right side of every page
  • Review the Department’s “Bureaus and Offices” organizational list
  • Check our top index pages:
    • About State
    • Policy Issues
    • Countries & Regions
    • Economics & Energy
    • Arms Control & Security
    • Democracy & Global Affairs
    • Public Diplomacy & Public Affairs
    • Assistance & Development
  • Scan the list of U.S. Embassies, Consulates, and Virtual Presence Posts

If you still cannot find something, Contact Us.

Thanks for your interest!

sleeping Aids , , ,

Medical debt's 'underreported' toll

September 13th, 2010

While the cost and provisions of the Affordable Care Act tend to take center stage in health care discussion, there are other health care issues that have significant impact upon Americans. One such lesser known story is the problem of medical debt.

Medical debt relates to families and individuals whose health care costs–regardless of insurance coverage–have placed them in serious financial trouble. The true extent of the medical care debt problem in the U.S. is uncertain, but is a portentous situation, according to some studies that have been conducted.

Legislation has also been drafted to tackle aspects of the problem. Earlier this year Rep. Mary Jo Kilroy (D-Ohio) announced that legislation she sponsored, H.R 3421, the Medical Debt Relief Act, has been reported out of committee, which means it may be soon brought to the House floor for a vote. Rep. Carol Shea-Porter (D-N.H.) has sponsored H.R. 901, the Medical Bankruptcy Fairness Act, which was the subject of a July congressional hearing.

What are the underlying issues with medical debt, and how serious a problem is it in the context of insurance changes and other implementations from health care reform? Below is an overview with input from experts on what is likely to be a growing story.

The legislation

While the Medical Debt Relief Act is fairly narrow in scope, the legislation addresses one of the collateral effects of such debt, damage to credit rating and financial stability. The purpose of the act is exclude from consumer credit reports medical debt that has been characterized as debt in collection for credit reporting purposes, and has been paid or settled.

According to the Congressional findings in the legislation, medical debt is “unique,” because “unlike consumer debt, Americans don’t get to choose when accidents happen or when their genetic traits will catch up to their health profile.” The findings go on to report that medical debt affects millions, and accounts for more than half of all non-credit related collection actions reported to consumer credit reporting agencies. Medical debt is also more likely to be in dispute, and not of good value in predicting future payment performance because the debt is atypical.

The Medical Bankruptcy Fairness Act is intended to offer certain bankruptcy protections for homeowners who have medical debt, to restore some bankruptcy protections for individuals who have experienced economic distress as caregivers to ill or disabled family members and provide an exemption from means testing debtors whose financial problems were caused by serious medical problems.

Continue reading Medical debt’s ‘underreported’ toll

Health Care , ,

positive pregnancy tests brand: equate (walmart), cycle day: 26

July 4th, 2010

Browse 7608 Additional Images

Browse 7608 Additional Images

IMPORTANT: Text, data, graphics, graphs and photos presented on this page are intended for personal use only. Any other usage as well as any derived work (papers, studies, re-prints, reproductions on web sites…) is prohibited without explicit written consent from Tamtris Web Services Inc., owner and operator of FertilityFriend.com.

FertilityFriend.com is a trademark of Tamtris Web Services Inc. All other trademarks are the property of their respective owners.

pregnancy Tests , , , ,

Choices shape lives, Bezos tells seniors

June 14th, 2010

Speaking at Princeton’s Baccalaureate service May 30, Jeff Bezos, the founder and chief executive officer of Amazon.com, urged the class of 2010 to pay close attention to the decisions they make, as those choices will shape their lives. “In the end, we are our choices,” he told graduates.

Photos: Denise Applewhite

Princeton student Pinto Adhola celebrated with his family at the conclusion of the Baccalaureate ceremony, with Jane Okoth at left and Simone Awor at right.

  • “We are What We Choose” remarks by Jeff Bezos
  • Images for news media
  • Baccalaureate press kit
  • All Featured Stories
  • |
  • Previous Featured Story
  • |
  • Next Featured Story

Choices shape lives, Bezos tells seniorsPosted May 30, 2010; 05:58 p.m.share | e-mail | printby Kitta MacPherson

Members of the class of 2010 enter the University Chapel for the Baccalaureate service, an interfaith worship service that is one of Princeton’s oldest traditions.

The founder and chief executive officer of the major Internet retailer Amazon.com made an impassioned plea to Princeton’s graduating seniors on May 30 to pay close attention to the choices they make in life, as they will dictate not only success, but happiness.

“When you are 80 years old, and in a quiet moment of reflection narrating only for yourself in the most personal version of your life story, the telling that will be the most compact and meaningful will be a series of choices you have made,” said Jeff Bezos, a 1986 Princeton alumnus, speaking at this year’s Baccalaureate ceremony. “In the end, we are our choices.”

Amazon.com founder Jeff Bezos enters the University Chapel with Princeton President Shirley M. Tilghman for the University’s 263rd Baccalaureate ceremony.

Bezos spoke slowly and emphatically, almost as if he were engaging in a heart-to-heart with each graduate at the ceremony, which is an interfaith worship service, and one of Princeton’s oldest traditions. He related an emotional incident from his childhood that drove home for him the lesson about the power inherent in making right — and wrong — decisions.

On a long road trip with his beloved grandparents, a 10-year-old Bezos decided to impress his grandmother with his talents for calculations, informing her that her intensive cigarette smoking would take nine years off her life. When instead of praising his mathematical prowess, she wept, his grandfather took him aside and gave him one of the great lessons of his life.

“My grandfather looked at me, and after a bit of silence he gently and calmly said, ‘Jeff, one day you’ll understand that it’s harder to be kind than clever,’” Bezos said. Cleverness is a gift, Bezos told the graduates, and kindness is a choice. “You can seduce yourself with your gifts if you’re not careful, and if you do, it’ll probably be to the detriment of your choices,” he said.

Karambir Khangoora was one of several seniors who read during the service, which included prayers and readings from various religious and philosophical traditions.

Gazing at the students, Bezos acknowledged the group’s giftedness and envisaged that those talents would be employed by many coming marvels. “We’ll invent ways to generate clean energy and a lot of it,” Bezos predicted. “Atom by atom, we’ll assemble small machines that will enter cell walls and make repairs.” Alluding to recent advances in synthetic biology, he said those experiments would probably continue to the point where humankind will not only synthesize life, “we’ll engineer it to specifications.” It may even come to pass, he said, that science will bring society to the verge of fully understanding the human brain.

“Jules Verne, Mark Twain, Galileo, Newton — all the curious from the ages would have wanted to be alive right now,” Bezos said.

The coming opportunities, he said, will require the world’s future innovators to employ their gifts and make important choices. “How will you use these gifts?” he said. “And will you take pride in your gifts or pride in your choices?”

Bezos graduated with highest honors and Phi Beta Kappa in electrical engineering and computer science. He founded Amazon.com, now the leading online retailer, in 1994.

Before starting Amazon.com, Bezos worked at the intersection of computer science and finance, helping to build one of the most technically sophisticated quantitative hedge funds on Wall Street for D.E. Shaw & Co. He also led the development of computer systems that helped manage more than $250 billion in assets for Bankers Trust Co.

Members of the class of 2010 were solemn during one of the last experiences they would share on campus.

Deciding to start his company 16 years ago was one of the most difficult choices of his life, he said. He had a wonderful job with a great boss and colleagues. But he had an idea that wouldn’t go away. He had read that Web usage was growing at 2,300 percent a year. “I’d never seen or heard of anything that grew that fast, and the idea of building an online bookstore with millions of titles — something that couldn’t exist in the physical world — was very exciting to me,” he said.

Bezos’ wife, MacKenzie Tuttle Bezos, a 1992 Princeton alumnus, told him she would back him up if he quit and started his company. The audience laughed when Bezos described his boss’ reaction. “He took me on a long walk in Central Park, listened carefully to me, and finally said, ‘That sounds like a really good idea, but it would be an even better idea for someone who didn’t already have a good job,’” Bezos said.

Bezos, however, decided to pursue his passion. And he is proud of his choice.

In her introduction of Bezos, Princeton President Shirley M. Tilghman praised him as “a dreamer and doer, entrepreneur and engineer” and “refreshingly unassuming even in the face of unimaginable success.” She also lauded him for “his exceptional ability to marry commerce and technology in creative ways” and “his sheer inventiveness and willingness to take the risks inherent in this process.”

Accompanied by colorful kites, seniors filled the chapel for the Baccalaureate service, which dates back to 1760, when President Samuel Davies addressed the class with remarks titled “Religion and the Public Spirit.”

Jack Breslauer, a Woodrow Wilson School senior, said he was touched by Bezos’ words. “He was incredibly sincere,” Breslauer said. “I really was struck by the fact that a person with his sort of astounding success was urging kindness and consideration of others. It resonated with me.”

Tani Brown, a senior religion major, appreciated Bezos’ directness and his air of humility. “He was speaking to us as fellow Princeton students,” she said. “It’s not so much that we shoulder a burden as that we bear a responsibility. And he was speaking to that and reminding us of that.”

The Schoppe family gathered in the shade outside of East Pyne Hall after the Baccalaureate service to celebrate with their Princeton students, twin sisters Jennifer and Christine.

Princeton’s Baccalaureate service is an end-of-the-year celebration focused on members of the senior class. It includes prayers and readings from various religious and philosophical traditions. The earliest recorded Baccalaureate address — titled “Religion and the Public Spirit” — was delivered by President Samuel Davies in 1760 to the 11 members of the graduating class. Since 1972, the address has been given by a speaker chosen by the president after discussion with class leaders.

The May 30 service was webcast live and will be available for later viewing. End-of-the-year activities will continue with Class Day on Monday, May 31, and Commencement on Tuesday, June 1.

quitting Smoking , , ,

In 'A Visit From the Goon Squad,' novelist writes serious fiction for Facebook …

June 13th, 2010

US writer Barbara Kingsolver wins Britain’s Orange Prize for Fiction with ‘The Lacuna’

June 9th, 2010 US writer Kingsolver wins Orange Prize for Fiction…LONDON — American novelist Barbara Kingsolver took home the prestigious Orange Prize for Fiction on Wednesday with her sixth novel, “The Lacuna,” beating bookmakers’ favorite Hilary Mantel. Kingsolver, who had not published a novel in nine years, said she was “stunned and thrilled” as she received the 30,000 pound ($45,000 ) prize — open to any novel by a woman published in English — at London’s Royal Festival Hall.

Dominican-American novelist Junot Diaz, author of ‘Oscar Wao,’ elected to Pulitzer Prize board

May 21st, 2010 Novelist Junot Diaz elected to Pulitzer boardNEW YORK — Dominican-American novelist Junot Diaz has been elected to serve on the Pulitzer board, which awards the most prestigious prizes in journalism. Diaz, who won the 2008 Pulitzer Prize for Fiction for “The Brief Wondrous Life of Oscar Wao” and teaches creative writing at the Massachusetts Institute of Technology, said Friday that it was an “extraordinary honor.”"It certainly taps into the thing I love to do best, which is to read,” said Diaz, who was born in Santo Domingo, Dominican Republic and immigrated to New Jersey as a child.

Gen Y are shopaholics and Gen X looks for quality stuff: Oz study

May 20th, 2010 MELBOURNE – Generation Y are shopaholics and the rather older Generation X have a taste for quality goods, according to new research on Australian shoppers. The analysis, conducted by research consultancy Directional Insights, split consumers into seven categories shopaholics, shopaphobes, shopping tolerators, quality seekers, price sensitive, traditionalists and online geeks, reported Australian commuter newspaper mX.

Felton’s Tearful Trip To Auschwitz

May 12th, 2010 HARRY POTTER star TOM FELTON has paid an emotional visit to Nazi death camp Auschwitz – calling the trip “mentally painful”. The British actor travelled to the site of the former concentration camp in Poland on Tuesday (11May10), the place where an estimated 1.1 million people died during World War II.

Author Sillitoe Dies

April 26th, 2010 British author ALAN SILLITOE has died, aged 82. He passed away at Charing Cross Hospital in London on Sunday (25Apr10), according to his son David.

Facebook accused of distracting kids from studies

March 25th, 2010 MELBOURNE – Popular social networking websites such as Facebook are having a distracting effect on school children and their studies, according to a survey. The poll, headed by Oxygen Factory, discovered nearly 80 per cent of students aged 11 to 18 said social networking sites were a distraction from their studies.

Clarke Breaks Leg In Motorcycle Hit-and-run

January 12th, 2010 Former GUNS N’ ROSES rocker GILBY CLARKE has been hospitalised after breaking his leg in a hit-and-run motorcycle accident. The bassist, who played with the Paradise City hitmakers for three years, was riding his bike on Sunday (10Jan10) when the crash occurred.

Joel Defends Mum Brinkley

January 5th, 2010 ALEXA RAY JOEL has defended her mum CHRISTIE BRINKLEY over allegations the singer’s hospital visit last month (Dec09) was prompted after a “dysfunctional” vacation with the supermodel. The young star, whose father is Billy Joel, was admitted to St.

Now, log onto Facebook, Twitter for jobs

January 1st, 2010 MELBOURNE – If you’re glued to Twitter and Facebook you may soon find a job, suggest media experts. According to consultant Laurel Papworth there were nearly 350million Facebook users across the world, which made the social networking site the best way to find a job.

Kid Cudi Ditches Twitter Over Impostors

December 11th, 2009 Hip-hop star KID CUDI has turned his back on social networking – because he’s sick of “sad” people duping his fans by using his name online. The Day N’ Nite hitmaker was an avid fan of websites including Twitter and Facebook, but he’s cancelled his accounts so his followers won’t be fooled by impostors.

Mellencamp’s Son Asks Facebook Fans For Help

December 2nd, 2009 Rocker JOHN MELLENCAMP’s son SPECK has called on the world’s Facebook fans to help him convince his dad to stop smoking. The youngster has begged his famous father to kick his nicotine habit and Mellencamp has agreed to quit if his son can convince a million people to join his online crusade.

Linden MacIntyre wins prestigious Canadian literature award for novel about abuse by

November 11th, 2009 Linden MacIntyre wins Canadian literature awardTORONTO — Linden MacIntyre, an investigative journalist who wrote a novel about sexual abuse by Catholic priests, has won one of Canada’s most prestigious literary awards. MacIntyre won the Scotiabank Giller Prize for his book “The Bishop’s Man” on Tuesday night.

Novelist Elmore Leonard to receive lifetime achievement award from PEN USA

September 30th, 2009 Novelist Leonard to receive PEN USA awardLOS ANGELES — Novelist Elmore Leonard will receive PEN USA’s lifetime achievement award at a December ceremony. Leonard, 83, has written over 40 westerns, crime novels and mysteries, including “The Bounty Hunters,” ”Road Dogs” and “Cuba Libre.”Many of his books — notably “Out of Sight,” ”Get Shorty” and “Be Cool” — have been made into films.

Prolific Western novelist Elmer Kelton, who wrote “The Good Old Boys,” dies at 83 in Texas

August 23rd, 2009 Western novelist Elmer Kelton dies at 83SAN ANGELO, Texas — Western novelist Elmer Kelton, whose novel “The Good Old Boys” was made into a TV movie starring Tommy Lee Jones, has died. He was 83. Myrtis Loudermilk, a director at Johnson’s Funeral Home in San Angelo, told The Associated Press that Kelton died Saturday of natural causes.

Meet Gen Z – the age of financially responsible, tech savy young ones

July 29th, 2009 MELBOURNE – They are responsible money-wise, have a strong work ethic and grown up on the staple diet of Facebook, Twitter – please make way for Generation Z. Born between 1995 and 2009, Gen Z makes up for 18 per cent of the Australian population, reports The Courier Mail.

quitting Smoking , , ,

Electronic Cigarettes » Blog Archive » A Smoker's Control – Quit …

May 30th, 2010

  • You know it’s your time to Quit!! With our program we help decrease cravings and withdrawal symptoms, provide a distaste for cigarettes, and assist in removing nicotine from the body!!
  • YOU are in control! Take as little or as much as YOU need to YOUR desired effect. Favorable side effect profile allows maximum results!
  • Calming effect increases confidence. Quit in as little as 3-7 days. Optional extra Craving Formula to extent your program an additional 4-6 weeks
  • Developed by a physician. Effective for THOUSANDS of people.
  • Smoking is too expensive. Taxes on cigarettes are increasing! Restrictions on WHERE you can smoke are increasing!!

Product Description
Quit smoking today! With this complete, three part system of Nutritional Support and Aroma Therapy, you get the support you need to help you break the habit! The three formulas are precision fortified with a variety of natural herbs, vitamins, and minerals. Effective for smokeless tobacco, snuff, dip, chew…
If it has tobacco, we can help!!

Nutritional Support (64 Capsules): This synergistic herbal blend helps alleviate nicotine cravings and withdrawl j… More >>

A+ Smoker’s Control – Quit Smoking Cessation Program – All Natural, No Nicotine!!

This entry was posted on Saturday, May 29th, 2010 at 10:58 pm and is filed under Articles and News

quitting Smoking , , , , ,

Autism has a few takers to try the Alternative Treatments

May 16th, 2010

According to the CDC estimates that about one in 110 children in the U. S have an autism spectrum disorder , the umbrella name given to a graoup of disorders that can range from the mild to the severe that often affect social and communication abilities. The two new studies also show Gastrointestinal symptoms occur in almost 50 percent of children with autism spectrum. A total of 1,185 children were examined and found 45 percent had GI symptoms.

Dr. Daniel Coury, medical director of the ATN and of Ohio Sate University said, “These findings suggest that better evaluation of GI symptoms and subsequent treatment may have benefits for these patients. Primary care physicians and specialists should ask families about these symptoms and address these as part of the overall management plan for the child or adolescent with autism spectrum disorders”. Philele Mlotshwa of Swapol, which is organizing the event, “They are the heroes yet no one has gone to them to say we recognize your efforts. They are holding together the social fabric of communities across the continent. Grandparents have always played an important role in solving disputes and as a source of knowledge. But now the younger generation is not there: people aged 29 to 49 are dying from HIV-Aids We is seeing a demographic of the elderly and the very young that’ve lost their parents”.

The study does show that younger children with autism were less likely than older kids to receive psychotropic medications however the study does raises some questions about how, when and even why these medications are being used in autism treatment. Coury also said in a statement, “Primary care physicians and specialists should ask families about these symptoms and address these as part of the overall management plan for the child or adolescent with autism spectrum disorders”.


relaxation Aids , , ,

John Graham-Cumming: You don't have to be gay

April 26th, 2010

Scarlett Fever

April 24th, 2010

BRIGHT STAR:  Stunning Scarlett Johansson is Mango’s newest muse.  The Barcelona-based clothing manufacturer and retailer’s “Scarlett” collection includes romantic separates with delicate, feminine detailing.  Far removed from the glitz and drama you might associate with this Hollywood hottie, the looks here are more boho than Rodeo.  Prices are also down-to-earth, with most pieces ringing in well below the $100 mark.  This sweet and sexy floral number is $99.90, for example, and don’t miss plenty of perfect accessories to match.  GET IT:  Scarlett by Mango, shop online at Mango.com.

feminine Care , ,

How to profit from Obama's health care reforms – Pharmaceutical …

April 17th, 2010

Keywords: USA, Health care reform, How to profit, Investment, Merck & Co, Pfizer, Bristolo-Myers, Crucell

Article | 16 April 2010

  • Print This

Despite fears to the contrary, US big pharma looks set to do well out of US President Obama’s healthcare bill. So now’s a good time to buy in, says David Stevenson, writing in Money Week and presented here with thepublishers approval (go to moneyweek.com for original story).

After months of tussle and bile-filled debate, US healthcare policy has just seen its biggest reform for four decades. Last week, Barack Obama managed to push through big changes to the American health system in the face of substantial opposition. And despite what you might expect, one of the biggest beneficiaries could be Big Pharma. Indeed, Obama’s changes could be just the catalyst needed to inject new life into the sector.

Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.

We¹ll have more on that later. First, let’s take a look at those health care reforms. We covered them in detail in last week’s issue, but in short The Patient Protection and Affordable Care Act aims to provide “quality health insurance coverage for all Americans”.

Note the key word: ‘coverage’. America hasn’t introduced its own version of the NHS (which is what many health industry lobbyists had feared most). The Act is more like the health care “equivalent of Britain’s compulsory car insurance”, says Simon Jenkins in the Evening Standard.

Health care cover will be extended to the 32 million Americans who are now uninsured ­ typically because they can’t afford rising premiums, or because insurers have already deemed them too ill to qualify for cover. An estimated 24 million who don’t have health cover will be able to get tax credits to buy it on new state-approved insurance ‘exchanges’. An extra 16 million will become eligible for Medicaid, the government-funded health scheme for those on low incomes.

Addressing the Doughnut hole

The ‘doughnut hole’ is also being addressed. This is a gap affecting millions of over-65s who get Medicare health cover and currently have to pay prescription expenses over $2,700: they only re- qualify for cover if their costs top $6,154. The new rules will give them flat rebates and discounts on brand-name drugs.

Meanwhile, insurance companies will face more controls on stopping coverage, for example for those who become sick. But though the insurance industry faces tighter rules, it’s relieved that one of its worst fears ­ a government-run scheme competing directly with the industry – hasn’t happened. Increased coverage of course also means that insurers will get millions of new customers, while premiums are eventually likely to rise.

Insurers aren’t the best health care play

That sounds good. And it might persuade you to buy shares in one of the major life and health insurers. For example, on a current year p/e of below 13, Aetna (US: AET) doesn’t look too these insurance stocks is downright poor. Aetna pays an annual dividend yield of only 0.6%. If you think that’s bad, it’s still three times the level Cigna shareholders get.

Second, investors have been steadily factoring much of the potential good news for insurers into their share prices. Both stocks have outperformed the overall indices by quite a distance over both the short and the long term. Indeed, since 1998, Cigna has beaten the S&P 500 index by more than 50%, while Aetna has shot the lights out with a near-200% outperformance.

That takes us back to US big pharma. The contrast with the relative performance of the insurers is quite startling. Drug stocks have been underperforming for ages. The S&P Pharma index has undershot the overall market by 30% over the last seven years. So why has the sector fallen so far out of favour ­ and why should the new healthcare laws help?

Big pharma’s big problems

In the market¹s eyes, the two main problems for medicine manufacturers have been what’s known as the ‘patent cliff’ and possible damage from President Obama’s health care reform. The patent cliff is the likely loss of high-margin sales by the world’s top drug-makers as many of their best-selling drugs (known as ‘blockbusters’) come off patent. When this happens, the drugs can then be copied by generic rivals and sold more cheaply. Industry experts reckon the global hit could be as big as $140 billion by 2016. Even for a business that’s likely to ring up worldwide sales in 2010 of more than $825 billion, that¹s still a big bite.

Then there have been the fears over healthcare reforms. Analysts have been concerned about the danger of low-cost drug imports, and tough pricing deals and rebates being imposed by Medicare and Medicaid. So the sector’s shares have suffered horribly.

Take a look at the chart on the right. The blue line is the stock market valuation of the US pharma sector. The left-hand scale shows how the price/earnings (p/e) ratio has dropped from more than 40 in 1999 to around 11.5 today. Investors have gone from expecting great things from the sector to constantly worrying about being disappointed. That sort of massive de-rating would normally go hand-in-hand with a collapse in profits.

But has this happened with drug stocks? Not at all. In fact, it’s the exact opposite. Despite all the market’s fears, American big pharma has kept delivering the goods. Look at the red line on the chart. This shows the earnings per share (EPS) generated by the S&P Pharma index over the past 12 years (rebased to 100): it¹s an increase of some 175%. Even better, this is near-straight upward line, too. That means drug-stock profits and cash flows have grown consistently year-on year.

Compare that to the green line. This shows the earnings generated by the overall S&P 500 index. Not only are these more variable than the pharma sector, they’re up just 60% over the same period. What’s more, the ‘normalised’ p/e on the S&P 500 index ­ which measures the average of ten years’ earnings ­ is now 21.3. That compares with the long-term average of 16.4. This means investors are valuing American shares overall at almost twice the level of US big pharma.

In other words, even if the patent cliff causes a hiccup in drug companies’ profits, the damage is fully “baked into the stocks”, says Timothy Fidler at Ariel Investments. He adds that the big US pharma firms with their strong profits, cash flows and high returns on capital, are “good, contrarian investments”, with some now trading at, or even below, the value of their drug pipelines.

And as for health care reform, not only have most of the industry’s fears proved groundless, the new deal is actually likely to prove very good news for America’s drug firms. “Pharma came out of this better than anyone else,” says Washington health analyst Ramsey Baghdadi. “I don¹t see how they could have done much better.”

“Costly brand-name biotech drugs won 12 years’ protection against cheaper generic competitors, a boon for products that comprise 15% of pharmaceutical sales,” points out Alan Fram in Associated Press. And although “the industry will have to provide 50% discounts beginning next year to Medicare beneficiaries in the ‘doughnut hole’ gap”, cheaper drugs and

The overall impact isn’t entirely certain, says Fram, but “Goldman Sachs suggests the overhaul could mean ‘a manageable hit’ of tens of billions of dollars over the coming decade while bolstering the value of drug company stocks”. And others expect profits, not losses, ‘of the same magnitude.’

Baghdadi projects a “$30 billion, 10-year net gain for the industry.” In a nutshell, it looks like the stockmarket’s view of US drug stocks is about to change. Healthcare reform should be the catalyst for kick-starting the performance of this neglected sector.

The best US big pharma stocks to buy

So which stocks should you buy? Here are four, all with low p/es and well-above-average yields. The largest of the US drug makers is Pfizer (NYSE: PFE). At $17.21, it¹s on a 2010 p/e of below eight, and has a prospective dividend yield of 4%. That¹s not bad when you consider that the S&P 500 average is closer to 2%. “Pfizer is more a cost-cutting than growth story,” says The Motley Fool. It has “massive economies of scale…and financial resources, all of which are advantages in the pharma space”.

The slightly more expensive Merck & Co (NYSE: MRK) is on a multiple of 11 this year, and also yields 4%. “It¹s my favourite pharma stock,” says John Dorfman in BusinessWeek. “It has 20 drugs in Phase III trials, the most advanced stage of drug development, and another 20 in Phase II. Pre-tax margin, 56% last year, could fall a lot and still dwarf insurers’ profit margins.”

Meanwhile, Bristol-Myers Squibb (NYSE: BMY) at $26.70 is the most expensive of the group, on a current year p/e of 12, with a 4.8% prospective yield. But that’s still hardly expensive as “longer-term, the company expects a period of sustained earnings growth beginning in 2014″, says Chris Schott at JP Morgan. The cheapest of the four is Eli Lilly (NYSE: LLY), which at $35.56 is on a 2010 p/e of just 7.5, and a prospective yield of 5.7%.

It’s time to stockpile vaccines

Increased certainty over the extent of Obama’s reforms have lifted one of the big clouds hanging over the pharmaceutical sector. That could be enough of a catalyst to spark a resurgence of investor interest in the industry. But the other big question is, with blockbuster drugs ever harder to come up with, how are drug companies going to make their money in future?

One answer to this question is vaccines. Traditionally seen as a high-risk, low-profit-margin backwater of the pharmaceutical industry, that image has changed over the past decade or so. Much of that is down to fears over influenza pandemics. Concerns over ‘bird flu’ and its variants persuaded governments to stock up on vaccines for emergencies. And they were willing to pay enough to make it worth the vaccine-makers’ while.

Indeed, between 2004 and 2007, global vaccine sales leaped by an average of 32% a year, with flu vaccine leading the way. As Paul Waldie and Grant Robertson point out in Canadian newspaper The Globe & Mail, “that is roughly four times faster than any other pharmaceutical product”. Now the vaccine business is worth $24 billion a year. Some experts reckon that will grow to around $40 billion by 2012.

But it’s not just about flu. More complex vaccines aimed at tackling new areas, such as cancer, have been developed and launched. One major breakthrough came in 2000 when Wyeth made Prevnar, a vaccine that helped combat pneumonia and ear infections in infants. Annual sales have grown to more than $3 billion, making it a blockbuster product. Pfizer, which now owns Wyeth, is working on an adult version of the vaccine, which it expects will generate annual sales of around $1.5 billion.

In an era when the biggest threat to pharmaceutical firms has been generic competition, vaccines are also a tough business for other companies to break into. A new manufacturing plant can cost up to $1bn. As Glaxo’s Phillipe Monteyne tells The Globe & Mail: “The barriers to enter the market are extremely high. You don’t become a vaccine-maker overnight. That’s why we have a few big players, and very few only.”

The focus on prevention rather than cure is also appealing at a time when governments are looking to cut healthcare costs. It’s much cheaper to give someone an injection than treat them for the disease itself. And you can be sure the drug firms will keep pushing their vaccines into new markets. You might have noticed studies cropping up in the news that have found that some head and neck cancers which are connected to the same virus that causes cervical cancer are becoming more prevalent in young people. This suggests that boys as well as girls should all be vaccinated against the same virus.

Of course, this raises questions of cost-effectiveness. Just how necessary are certain vaccines? Should we all be vaccinated against chicken pox, for example? It may seem like a question for public health officials, but it¹s something for investors to be aware of. Vaccination can be an emotive subject, and as the MMR debacle showed, it doesn’t take much to damage uptake of any jab that falls under suspicion.

But for now the sector is on the up. So what’s the best way to profit? You could buy into one of the big pharma firms with exposure to the sector, such as GlaxoSmithKline. We’ve nothing against Glaxo, indeed we’re fans of the stock.

The case for Dutch group Crucell

But a more interesting, purer play on vaccines is Dutch biopharma group Crucell (Amsterdam: CRXL), says Dr Mike Tubbs in his Research Investments newsletter. It’s the largest independent vaccines company in the world, and within the global top six for vaccine sales. The group has several vaccines already on the market, which it sells around the world, and there are many more in its pipeline. These include a yellow fever vaccine in very late stage development, plus vaccines for rabies and TB in phase II development. In early stage development are vaccines for malaria, ebola, HIV and hepatitis C. All are being produced with partners.

The company also licenses out its own technology, which “is rapidly becoming an industry standard for the development and manufacture of vaccines, therapeutic proteins and gene therapy products”. It has 14 licensees for vaccines, 30 for therapeutic proteins and eight for gene therapy, with a list of users that includes GSK, Novartis, Merck and Sanofi.

But most exciting of all, Crucell is developing a universal flu vaccine, which will be able to target any type of flu strain, from ordinary seasonal flu to the dreaded swine and bird flu variants. Partly on the basis of this product, consumer healthcare giant Johnson & Johnson has invested more than 300 million euros to take an 18% stake in the firm.

The financials look solid. ­ The group first moved into the black in 2008, with an operating profit of 7.9 million euros, since when earnings have grown rapidly. For its full-year 2009, operating profit came in at 39 million euros, a record result. And the company is sitting on an extremely healthy-looking cash pile of 428 million euros ­ up from 173 million euros at the end of 2008.

That’s enabled it to increase its spending on research and development by a third, at a time when most pharmaceutical companies are looking to cut back. Better yet, the company is a decent play even if you are concerned ­ as we are ­ about the prospects for a double-dip recession. As Tubbs points out, “vaccines are needed irrespective of what the economy does. That makes Crucell a great recession-resistant holding.” He reckons you should buy the stock at any price up to 18 euros.

Health Care , ,

Nabi closes license deal with GlaxoSmithKline

March 31st, 2010

ROCKVILLE, Md. — Nabi Pharmaceuticals said Monday it closed an option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline.

The deal is potentially worth more than $500 million, including a $40 million upfront payment to Nabi and future milestone and royalty payments.

Nabi shareholders voted in favor of the deal on Tuesday. The companies announced it in November.

Nabi is developing NicVAx, which is intended to train the immune system to make antibodies that will attach themselves to nicotine. The goal is to keep the nicotine molecules from reaching the brain so people can quit smoking and not start again.

GlaxoSmithKline, based in London, will also start developing a second-generation version of the vaccine.

Shares of Nabi rose 6 cents to $5.57 in afternoon trading. GlaxoSmithKline lost 14 cents at $37.40.

quitting Smoking , , , ,

Lyon69's Party #2 : the Racing Experience | Blog Made In LYON

March 30th, 2010

En mars, Lyon69.net vous a fait vivre l’expérience d’un Chili bien relevé au bistrot Chez Thibault. En avril, on pousse beaucoup plus loin le curseur de l’adrénaline en vous proposant de vivre l’expérience d’une course automobile !

En effet, la prochaine Lyon69’s Party se déroulera à l’I-Way, le centre de simulation automobile unique au monde !

Ça se passera le mardi 13 avril, à 19H, au 4 Rue Jean Marcuit, Lyon 9ème.

A cette occasion les 6 Pescarolos du simulateur Endurance seront mises à  votre disposition !

feminine Care , , , ,